Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALPAC
2024-516336-97-00Phase 2Authorised
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil, oxaliplatin and levoleucovorin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Belgian Group of Digestive Oncology. Primary endpoint: Progression-free survival rate at day 85. Planned start Sep 2024; status: authorised.
02
Drugs
irinotecanfluorouraciloxaliplatinlevoleucovorin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516336-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516336-97-00.